Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Phase IV Clinical Trial of Quadrivalent Influenza Virus Split Vaccine to Evaluate the Safety and Immunogenicity in Healthy Population Aged 3-8 Years

NCT05138705 is registered in ClinicalTrials.gov with Shanghai Institute Of Biological Products as lead sponsor.

NCT NCT05138705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05138705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Phase IV Clinical Trial of Quadrivalent Influenza Virus Split Vaccine to Evaluate the Safety and Immunogenicity in Healthy Population Aged 3-8 Years
Lead sponsor
Shanghai Institute Of Biological Products
Phase
Phase 4
Overall status
Completed
Start date
December 14, 2021
Completion date
August 5, 2022
Enrollment
380 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human